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A pilot, open labelled, randomised 
controlled trial of hypertonic saline 
nasal irrigation and gargling for the 
common cold
sandeep Ramalingam  1, Catriona Graham2, Jenny Dove1, Lynn Morrice3 & Aziz sheikh3
there are no antivirals to treat viral upper respiratory tract infection (URtI). since numerous viruses 
cause URtI, antiviral therapy is impractical. As we have evidence of chloride-ion dependent innate 
antiviral response in epithelial cells, we conducted a pilot, non-blinded, randomised controlled trial 
of hypertonic saline nasal irrigation and gargling (HsNIG) vs standard care on healthy adults within 
48 hours of URTI onset to assess recruitment (primary outcome). Acceptability, symptom duration 
and viral shedding were secondary outcomes. participants maintained a symptom diary until well 
for two days or a maximum of 14 days and collected 5 sequential mid-turbinate swabs to measure 
viral shedding. the intervention arm prepared hypertonic saline and performed HsNIG. We recruited 
68 participants (2.6 participants/week; November 2014-March 2015). A participant declined after 
randomisation. Another was on antibiotics and hence removed (Intervention:32, Control:34). Follow up 
data was available from 61 (Intervention:30, Control:31). 87% found HSNIG acceptable, 93% thought 
HSNIG made a difference to their symptoms. In the intervention arm, duration of illness was lower by 
1.9 days (p = 0.01), over-the-counter medications (OTCM) use by 36% (p = 0.004), transmission within 
household contacts by 35% (p = 0.006) and viral shedding by ≥0.5 log10/day (p = 0.04). We hence need a 
larger trial to confirm our findings.
The common cold is a viral upper respiratory tract infection (URTI). Adults and children get 2-3 and 6-7 attacks 
respectively of URTI annually1,2. In 2016 the UK lost 34.0 million work days (33.1% of total) due to minor 
illnesses such as URTI3. An episode of URTI cost €266.41, €273.36 in Cardiff and Southampton respectively4. In 
the US, 72% of respondents had URTI in the past year costing $40 billion annually2. Outbreaks of respiratory tract 
infections are common in hospitals and care homes with significant morbidity and mortality5. URTI can lead to 
lower respiratory tract infections (LRTI) such as pneumonia, or cause exacerbations in individuals with asthma, 
chronic obstructive pulmonary disease (COPD), and cystic fibrosis6. Since URTI precedes LRTI, early interven-
tion could prevent these complications.
At present, there are no antiviral agents to treat the common cold. Though rhinovirus is called the “common 
cold virus”, a large number of viruses cause URTI7. Hence, specific antiviral treatment is impractical, and we 
need an intervention effective against multiple viruses. Jalaneti (cleaning the nasal passages with salt water), an 
ancient practice from India is recommended in Yogic texts for the common cold8. A significant reduction in sore 
throats and colds was reported when Australian wood-workers performed Jalaneti for a year9. Three randomised 
controlled trials (RCT) report the efficacy of salt water for acute URTI. Adam et al. reported the lack of improve-
ment in symptoms or duration of illness in adults with a common cold or bacterial rhinosinusitis [hypertonic 
saline (HS)/normal saline (NS) sprays thrice/day vs. standard care]. However, individuals with a common cold 
who received HS sprays said they would use it again (p = 0.007)10. Sea-water sprays (six-times/day) significantly 
reduced sore throat, nasal secretions, decongestant/mucolytic use in children with URTI11. A Cochrane review 
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concludes that the evidence is very limited12. In a recent report, both NS and sea-water drops (thrice/day) reduced 
the severity of URTI symptoms in young children13.
Inhibition of viral replication in the presence of chloride/halide salts was reported in the 1960’s14. We have 
recently reported laboratory evidence that non-myeloid cells (e.g. epithelial, fibroblast and hepatic cells) have an 
innate immune mechanism, which is augmented in the presence of salt (NaCl)15. In cell culture models, DNA, 
RNA, enveloped and non-enveloped viruses are all inhibited in the presence of NaCl15. The antiviral effect is 
dependent on the availability of chloride ions (and not sodium ions)15. In the presence viral infection and the 
availability of NaCl, cells utilise the chloride ions to produce hypochlorous acid (HOCl)15. Since HOCl is the 
active ingredient in bleach, which is known to have an antiviral effect, the mechanism could be augmented by sup-
plying chloride ions through NaCl to treat infections. Here, we report the results of the Edinburgh and Lothians 
Viral Intervention Study (ELVIS), a pilot RCT of hypertonic saline nasal irrigation and gargling (HSNIG) versus 
standard care in adults with URTI to determine if we can recruit and retain participants in Edinburgh and to get 
initial information on acceptability, duration of symptoms, and viral shedding.
Results
We recruited 68 participants over 26 weeks between October 2014 and March 2015 (2.6 participants/week: Fig. 1). 
We excluded two (n = 66) [one declined after randomisation, and the other was on antibiotics] and randomised 
32 to the intervention arm and 34 to the control arm (Fig. 2). The majority (76%) were women. Most (76%) 
preferred paper forms over online feedback. Most (Intervention: 94%, Control: 91%) returned the daily forms, 
end-of-study form (Intervention: 88%, Control: 85%) and swabs (Intervention: 88%, Control: 91%). Of the 
sixty-six participants, five did not return daily forms. Of the sixty-one, four did not return end-of-study forms. Of 
the fifty-seven, three did not return samples. All forms and samples were hence available in fifty-four individuals.
80% in the intervention arm used 3% HS, while 9% each used 2.5%, 2% HS. All but one used Cornish sea salt. 
One participant left without the sea salt and used another brand available at home. An individual in the control 
arm reported performing nasal irrigation but provided no further information.
The baseline characteristics, symptom severity and degree of interference with daily life were similar in both 
arms (Table 1). We identified an aetiology in the baseline sample of 73% (48/66) of participants (Table S1). 
Amongst these, 56% were rhinovirus and 31% were coronaviruses (COV), with the rest due to enterovirus, influ-
enza A virus, parainfluenza virus type 3 (PIV-3), respiratory syncytial virus (RSV) and human metapneumovirus 
(HMPV). We detected dual infections of rhinovirus with an enterovirus/COV HKU1 in two.
Most participants completed the “WURSS-21-Scot” daily until they were well (i.e. a score of 0) on two days 
(please see Fig. S1 for daily forms). Intervention and control arms completed the symptom diary for a mean (SD) 
of 6.8 (2.2) and 8.7 (3.3) days respectively. The intervention arm hence had a reduction in duration of illness by 
1.9 days (95% CI = 0.4 to 3.3) (p = 0.01) (Fig. 3). The duration of illness was significantly lower (p = 0.01) even if 
the first day participants felt well was the end-point [Mean (SD) Intervention: 6.0 (2.4); Control: 8.0 (3.4) days]. 
Participants performed HSNIG for a median of 5 days (IQR: 3 to 6) and at a median of thrice a day (IQR: 2 to 3) 
(Fig. 3).
There was a significant reduction in the duration of runny nose (1.8 days, 95% CI:0.4 to 3.2, p = 0.01), blocked 
nose (2.7 days, 95% CI:1.2 to 4.1, p < 0.001), sneezing (1.5 days, 95% CI:0.3 to 2.9, p = 0.02), cough (2.4 days, 
95% CI:0.9 to 4.0, p = 0.003), hoarseness of voice (1.7 days, 95% CI:0.2 to 3.1, p = 0.02) (Fig. 3; Supplementary 
Table S2).
We could calculate the average WURSS-21 score and EQ-VAS scores from the diaries (please also see sup-
plementary results). The median (IQR) average WURSS 21 score in the intervention group was 13.2 (7.6 to 
16.4) [n = 30] and 16.9 (9.9 to 24.7) [n = 31] in the control arm (p = 0.09). The mean (SD) average quality of life 
Figure 1. Expected and actual recruitment: Recruitment of participants from the 1st October 2014 till close 
of recruitment on 31st March 2015. If we take the full 26-week period, this would result in an average of 2.6 
participants per week over the study period. However, if we were to take the first and last recruitment dates this 
give a period of 20 weeks which results in an average of 3.4 participants per week.
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measure (EQ-VAS) over the study duration was higher at 74.3 (12.1) [n = 30] for the intervention and 70.8 (15.5) 
[n = 31] in the control arm. The difference in means of 3.4, 95% CI for difference (−3.7 to 10.6) was not signifi-
cant (p = 0.338) (Supplementary Table S3).
Excluding those with no virus detected in the baseline sample [Intervention: 5 (16%); Control: 12 (35%)], 
samples on days 1–4 to estimate viral shedding was available in 25 and 20 individuals in intervention and control 
arms respectively (Fig. 4). In four individuals [a COV and a rhinovirus each per arm], no virus was detectable on 
days 1–4. Details of symptom severity, viral shedding and HSNIG are in Fig. 4.
The median (IQR) reduction in viral shedding between baseline and end-point sample in the intervention 
arm was −2.23 log10 (−3.04 to −0.32) [n = 26] and −1.51 log10 (−3.30 to −0.55) [n = 21] in the control arm 
(p = 0.9). (see supplementary results). We then estimated the proportion of individuals with viral shedding by 
≥0.5 log10/day between arms (see supplementary results). Four individuals in the intervention arm had paramyx-
ovirus infection but none in the control arm. As paramyxoviruses have a longer life cycle16,17, incubation period18, 
duration of viral shedding19 and illness19,20 compared to rhinovirus21–24, the data was analysed after removing 
these individuals. A higher proportion in the intervention arm had a fall ≥0.5 log10/day compared to controls 
[Intervention 73% [n = 16/22], Control 43% [n = 9/21], difference −30%, 95% CI for difference in proportion 
(−58 to −2) p = 0.04].
End-of-study forms were available from fifty-seven individuals (Table 2). Over-the-counter medications use 
(OTCM) use was 36% lower in the intervention arm (95% CI 14 to 59) (p = 0.004). Amongst participants who 
were not living alone, 35% fewer individuals in the intervention arm (95% CI 10 to 60) had household contacts 
developing URTI after them (p = 0.006).
Screened prior to eligibility assessment 
(n=171)
Assessed for eligibility (n=72)
Excluded (n=99)
• Did not meet inclusion criterion (n=76)
• Declined to parcipate (n=15)
• Other reasons (i.e. unable to aend 
within 48 hours(n=8))
Randomized (n=68)
Excluded (n=4)
• Did not meet inclusion criterion (n=4)
Allocated to Intervenon  (n=33)
• Received allocated intervenon (n=32)
• Did not receive allocated intervenon
(Declined to perform HSNIG) (n=1)
Allocated to Control (n=35)
• Received allocated intervenon (n=34)
• Removed (was on anbiocs) (n=1)
Number with follow-up (n=30)
Lost to follow-up, reason unknown (n=2)
Number with follow-up (n=31)
Lost to follow-up, reason unknown (n=3)
• Number returned daily form (n=30)
• Number returned swabs (n=28)
• Number returned end-of-study form (n=28)
• Number returned daily form (n=31)
• Number returned swabs (n=31)
• Number returned end-of-study form (n=29)
Screened
Enrollment
Allocaon
Follow-up
Assessment
Figure 2. Consort Flow diagram: Based on the “CONSORT extension for Pilot and Feasibility Trials Flow 
Diagram” (http://www.consort-statement.org/downloads/extensions - Accessed 04/12/2018).
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We received feedback on HSNIG from 28/32 participants (Table S4). 93% said that HSNIG made a difference 
to their symptoms. They found HS easy to prepare (100%). Most preferred to prepare solution in bulk in a flask 
(86%) and preferred using a small bowl to perform HSNIG (75%). Most considered the procedure either com-
fortable or moderately comfortable (89%) and the majority (86%) were happy to perform the procedure outside 
home. The most commonly reported effects were that it helped clear the nose/reduced stuffiness (n = 16), made 
it easier to breathe (n = 7), speeded up resolution of symptoms (n = 5), reduced the severity of the illness (n = 3) 
and improved sleep (n = 2). 60% of participants were likely to use HSNIG in the future and 25% of participants 
were undecided if they would use HSNIG in the future. The figure increased to 86% if the procedure could be 
made more convenient. Most (71%) however said they were unlikely to use HSNIG as a prophylactic measure.
Discussion
Our pilot RCT confirms that it’s possible to recruit and retain participants for a full trial of HSNIG with 3% 
HS. HSNIG reduced the duration of illness (22%), OTCM use (36%) and illness in household members (35%). 
When individuals infected with similar viruses (rhinovirus, coronavirus, enterovirus and influenza virus) were 
compared, 30% more individuals had reduction in viral shedding by ≥0.5 log10 per day in the intervention arm. 
This could explain both the reduction in the duration of illness and transmission to household contacts in the 
intervention arm. However, though the difference between the baseline and end-point samples was larger in the 
intervention arm than the control arm, the difference was not significant (although this study was not powered 
to detect differences in these measures). In participants who stopped HSNIG before day four, 54% (7/13) had an 
increase in viral shedding. There was also an increase/stabilisation of symptoms in 50% (8/16) before symptoms 
resolved. In fact, four individuals felt the need to restart HSNIG for one or more days (Fig. 4). These finding along 
with the lower rate of symptomatic household contacts in the intervention arm suggest that HSNIG helps reduce 
viral replication. Since viruses are shed during breathing and speaking7, measure that helps reduce viral shedding 
would help reduce transmission.
Recruitment was relatively easy though it involved regular email reminders. Advertising through social media 
could potentially help in future studies. A major concern was whether the population in Edinburgh would be 
happy to perform HSNIG. Surprisingly, only one individual declined to participate having met the trial nurse. 
Patient reported compliance with HSNIG was excellent. Participants performed HSNIG more times in the earlier 
part of the URTI and fewer times as symptoms improved, a trend which was in keeping with the severity of illness 
(Fig. 3). A surprisingly high proportion (86%) reported performing HSNIG outside their homes. 93% found 
HSNIG useful and 61% said they would perform HSNIG again if they had a cold, with a higher uptake if the 
procedure was more convenient. Alternatives such as nasal sprays are options, though they would not have the 
physical rinsing component of nasal irrigation. Hence a study to compare the two methodologies would be useful.
WURSS 21 score was not significantly different between the two arms, probably a reflection in the sample size. 
Neither was the EQ VAS score different between arms. EQ VAS score is an indicator of how a person feels on a 
given day and is not specific to URTI. It is hence probably not suitable for studies on URTI.
Our study has limitations. As a pilot with a primary outcome of establishing if a trial using HSNIG is viable, 
the study is not powered for efficacy end-points. We hence need a larger trial to confirm our findings. The lack 
of a placebo group is another limitation. Since our hypothesis was that the chloride ion has an antiviral effect, we 
were unable to use NS as a control as it could cause a reduction in symptoms. This is supported by results from 
earlier studies. For e.g. in a cross over trial (10 weeks twice daily nasal spray and 10 weeks without sprays with a 
Intervention (n = 32) n (%) Control (n = 34) n (%)
Age mean(SD) 34.6 (9.3) 39.4 (10.9)
WURSS-21 Score mean (SD) 41.6 (18.2) 43.9 (21.8)
EQ-VAS Score mean(SD) 65.9 (13.6) 63.7 (17.4)
Sex (Female) 24 (75) 25 (74)
Tobacco smoker - current 1 (3) 3 (9)
Tobacco smoker - ex 5 (16) 11 (32)
e-Cigarette smoker - current 0 (1) 1 (3)
e-Cigarette smoker - ex 2 (6) 0 (0)
Adults at home = 1 6 (19) 5 (15)
       >1 26 (81) 29 (85)
Children at home = 0 19 (59) 19 (56)
        1 7 (22) 5 (15)
        >1 6 (19) 10 (29)
No one unwell before them at home 19 (59) 21 (62)
Employment status: Full-time 20 (63) 21 (62)
        Part-time 7 (22) 5 (15)
        Education: Full time 4 (13) 4 (12)
        Other 1 (3) 4 (12)
Table 1. Baseline characteristics. WURSS: Wisconsin upper respiratory symptom survey; EQ-VAS: EuroQol-
Visual Analog Scale.
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two-week washout period), twice a day saline sprays significantly reduced nasal symptoms in military recruits 
compared to those with no intervention (p = 0.027). The number of episodes of URTI was lower in the period 
when saline sprays were used compared to the period when sprays were not used. However, the difference was just 
short of significance (p = 0.05)25. Our rationale also seems vindicated by a recent report suggesting that both sea 
water drops and saline drops were equally effective in treating children <2 years of age with URTI compared to 
symptomatic controls13. Sodium bicarbonate, though commonly used, is uncomfortable in the author’s personal 
Figure 3. Response from participants over the study period: Each line represents response of a participant over 
14 days. Data is shown by treatment group. The global severity question was “How unwell do you feel today”. 
The responses were graded from 0 (Not unwell), 1 (very mildly), 3 (mildly), 5 (moderately) and 7 (severely 
unwell). Likewise, each symptom was graded 0 (no symptom) to 7 (severe).
www.nature.com/scientificreports/
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experience. Recent evidence suggests that sodium ion also has an antimicrobial effect26,27. Hence, until a safe and 
comfortable placebo that contain neither chloride, halide or sodium ion is identified, placebo-controlled trials 
cannot be done.
Figure 4. Severity of symptoms, viral shedding and relationship to HSNIG and participant number in each 
arm: For each participant, the daily scores for the global question ‘how unwell do you feel today’ over 14 
days are represented by the grey background. For the intervention arm (shown on the left), the blue columns 
represent the number of times HSNIG was done that day. For both arms, change in viral shedding (as log values; 
Red line) is shown for the corresponding days.
www.nature.com/scientificreports/
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Another aspect that needs to be considered is the potential benefits of the simple process of flushing in the 
intervention arm. Even in the presence of a placebo arm, this cannot be answered. Further studies with different 
methodologies for supplying NaCl (e.g. hypertonic saline sprays, or aerosolised NaCl) may help answer this 
question.
In the absence of a placebo, we focused on viral shedding as an objective measure of antiviral activity due 
to HSNIG. There were more individuals without a detectable virus in the baseline sample in the control arm 
(12/34:35%) compared to the intervention arm (5/32:16%). This difference did not however reach statistical 
significance (p = 0.059) (Table S1). Though allergic rhinitis (history of allergy with current eye/nose itching or 
sneezing) was an exclusion criterion, it is possible that some of these individuals could have allergic rhinitis. Or, 
the infective aetiology might not have been detected in the nose swab. For e.g. sore throat was often recorded by 
those who did not have a detectable virus. As we collected a nose swab, it is possible that the aetiology could be 
picked up by including a throat swab along with a nose swab.
Viral shedding is difficult to quantify due to the variability in sampling and as most routine respiratory PCR’s 
are qualitative assays. We used self-collected mid-turbinate swabs (Copan, Italy) both for participants conven-
ience (no gag reflex) and as the swabs are designed with a stop which increases safety and should help reduce 
variation in sampling28. Since nasal irrigation could physically wash off the virus, we collected swabs first thing in 
the morning before HSNIG. We used eNAT, a transport medium that inactivates viruses and in which samples are 
stable at room temperature for at least two weeks. In our hands, samples in eNAT were stable for at least a week 
at room temperature and could be posted back to the laboratory for testing29. Where we identified a virus in the 
baseline sample, we tested all five samples in the same run to minimise inter-assay variability. To compare viral 
shedding, we converted CT values to log10 values. The baseline samples were hence tested on two occasions. The 
inter-assay variation between the two results was very low [mean (SD): 0.21 log10 (1.17)]. The cut-off of ≥0.5 log10 
per day used to determine reduction in viral shedding is more than double that of the inter-assay variation seen 
and hence is unlikely to be an artefact of the testing process. All these measures together have helped produce 
viral shedding data that could be compared between arms. In four individuals with a positive baseline sample, 
follow-up samples were negative. In two individuals a sample with a low CT (i.e. high viral copy) were followed 
by samples with undetectable virus. Since our consent did not include human DNA testing, we could not test for 
housekeeping genes and cannot be certain if these samples were properly collected. This need to be addressed in 
future studies.
We detected viruses in 73% of individuals, much higher than 40–55% reported by others30–32. This could be 
due to sampling within 48 hours of onset of illness. Though rhinoviruses and coronaviruses were the commonest, 
our study confirms that numerous viruses cause URTI. The viral load of the initial sample varied between individ-
uals and sequential sampling is important to detect change in viral shedding. A larger study would help determine 
the relative efficacy of HSNIG against different viruses.
At baseline, those infected with a virus other than rhinovirus had more individuals with runny nose and 
blocked nose (data not shown). Sore throat was often recorded in those without a viral aetiology. Hence a baseline 
throat swab for both bacteria and viruses may help determine the aetiology in these individuals.
Intervention Control
pn = 28 % n = 29 %
Took time off work 3 11 7 24 0.297*
  Days off work: 1 2 7 2 7
       2 1 4 1 3
       3 — 0 4 14
Took over-the-counter medication 14 50 25 86 0.004*
Attended GP — 0 2** 7
Attended hospital 1** 4 — 0
Household contact developed 
symptoms after participant 8/26 31 19 66 0.006
Performed procedure 28 100 1 3
Collecting swabs: Easy 19 68 18 62
       Moderate 7 25 3 10
       Difficult 2 7 8 28
Returning swabs: Easy 26 93 28 97
Diary completion: Easy 25 89 28 97
Form completion: Easy 25 89 27 93
Pre-study information – Useful 27 96 28 97
Instruction pack – Helpful 28 100 27 93
HSNIG video: Helpful 27 96 — —
Table 2. Feedback from participants at the end of study. *Using fishers exact test due to small counts or 
expected counts, **Reason for attending GP/hospital was not available, GP: General practitioner, HSNIG – 
Hypertonic saline nasal irrigation and gargling.
www.nature.com/scientificreports/
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The results of ELVIS are significantly different to that from Adam et al. which had many methodological 
issues. They compared 2% HS spray, NS spray (two squirts, thrice a day) and a control group in individuals with 
the common cold or rhinosinusitis10. Though sample size was similar to ELVIS (35–43/arm), individuals were 
recruited up to 3 weeks after illness onset. Very few had the common cold (12–17/arm), most had bacterial 
rhinosinusitis and 98% of them were treated with antibiotics. Despite these shortcomings, individuals with the 
common cold who received HS sprays said they would use it again (p = 0.007). To avoid these shortcomings, we 
selected only those with a common cold within 48 hours of onset, and who were not on antibiotic therapy.
Strengths of the study are the use of WURSS-21, a validated symptom score diary33, for up to two weeks, and 
sequential sampling over 5 days in otherwise healthy adults. With positive results in a controlled population, we 
can also look at more challenging population groups in subsequent studies. An alternative strategy would be to 
use HSNIG as a prophylactic tool. Wood workers who performed nasal irrigation twice a day for a year had fewer 
episodes of sore throat and colds9. Sea water sprays thrice a day, for 12 weeks in children significantly reduced 
reported illness, school absence and use of medication11. Though feedback regarding the use of HSNIG as a 
prophylactic tool was negative in our population, it may not be reflective of a population at high-risk for compli-
cations such as those with asthma/COPD.
Compliance was excellent in our study. We had online videos for preparation of hypertonic saline, performing 
HSNIG and collection of swabs both for providing instruction to participants and as a handy reminder if needed 
later on. Participants were all encouraged to prepare the solution and perform HSNIG in the presence of the trial 
nurse which we believe helped with compliance. Participants were also trained to collect the nose swab by the 
trial nurse. Hence a pragmatic approach (i.e. patient reported compliance) can be taken to reduce the burden to 
the participant and the cost of the study. However, in patient groups where compliance might be an issue, com-
pliance could be improved by using video monitoring of the procedures (HSNIG and collecting nasal swabs) via 
smart phones with support from the clinical team similar to the approach used for tuberculosis treatment34,35. 
The amount of salt used could also be measured at the end of the study. Tests for human DNA could be done to 
determine if swabs were actually collected before being introduced into the transport medium. Online data entry 
could be encouraged which would help reduce missing/incorrect data. Reminder messages (by text or email) 
could be sent to prompt regular data entry and return of samples. However, these decisions would need to be 
taken considering the population, the burden to the participant and the cost involved.
In this pilot, HSNIG significantly reduced the duration of URTI, OTCM use and illness within the household. 
A greater fall in viral shedding possibly explains the reduction in duration of symptoms and in symptomatic 
household contacts. This is in keeping with the lab evidence that cells utilise NaCl to mount an antiviral effect. A 
larger study powered for clinical and virological end-points is urgently needed to confirm these findings.
Methods
study setting and Design. We obtained ethical permission from the South-East Scotland Research Ethics 
Committee (13/SS/0079) and carried out the study in accordance with the Declaration of Helsinki (Clinical trials 
registration: NCT02438579, May 8, 2015). ELVIS was a pilot unblinded RCT of HSNIG to determine recruitment 
in Edinburgh as the primary outcome. Acceptability and compliance with HSNIG, quality of life, duration of 
symptoms and viral shedding were secondary outcomes. With a sample size of 27 per group we would be able 
to express the proportion of those who return the symptom score diary and samples within that group to within 
±19% based on a two-sided 95% confidence interval around an expected proportion of 0.5. With the two groups 
combined [i.e. a sample size of 54] we would be able to express a proportion to within ±13%. To allow for drop-
outs we planned to recruit up to 80 participants to have at least 30 participants per arm for analysis. The study was 
advertised through schools, libraries and general practices in Edinburgh and Midlothian areas, local newspaper 
coverage, emails within NHS Lothian, online, social media and the study website (www.elvisstudy.com).
Identification of individuals with a cold. Individuals with URTI were identified as done by Barrett et al.33,36 
Volunteers had to (1) answer “Yes” to “do you have a cold?” or “do you think you are coming down with a cold?”; 
(2) have at least one of first four symptoms: nasal discharge, nasal obstruction, sneezing, sore throat, headache, 
malaise, chilliness and cough and (3) have a Jackson Score of ≥2. Onset of URTI >48 hours, concurrent antibiotic 
use, pregnancy, known chronic conditions, immunosuppression, allergic rhinitis, inability to perform HSNIG and 
taking part in another medical trial were exclusion criterion. Volunteers met a trial nurse at a Clinical Research 
Facility at the Royal Infirmary of Edinburgh (RIE) or the Western General Hospital where informed consent was 
obtained, and participants were then randomised. Participants were centrally allocated into intervention and 
control arms using a minimisation algorithm containing sex and smoking status (current/not a current smoker) 
with a built-in random component to ensure allocation concealment.
Feedback. Participants had to maintain a daily form (Fig. S1) until they recorded “not unwell” (i.e. score of 0) on 
two consecutive days or for a maximum of 14 days or until the individual needed further treatment for URTI and 
then filled the end-of-study form (Fig. S2). The short form of the Wisconsin Upper Respiratory Symptom Survey 
(WURSS-21) was used to collect daily symptom data33. For use in the Scottish context, and with the authors con-
sent, the words “sick” and “plugged” were replaced with “unwell” and “blocked”, respectively (WURSS-21-Scot) 
(Fig. S1). Participants were asked to answer the global severity question: “How unwell do you feel today?” which 
was scored from 0 (not unwell) to 7 (severely unwell). If they scored >0, then symptoms and functional ability 
were graded 0–7. They then answered the global change question “Compared to yesterday, I feel my cold is” which 
was scored from 0 (very much better) to 6 (very much worse). Total WURSS-21 score was calculated by adding 
the scores for all except the first and last question. To calculate the mean WURSS-21 score, the scores for each 
participant were added and divided by 14. A mean value of EQ-VAS was calculated for each participant over the 
time questionnaires were returned as it was possible that participants may not score 100 even when a person’s cold 
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symptoms have completely resolved. Both arms documented OTCM use and if they contacted the general prac-
titioner (GP)/nurse for further management of their URTI. Feedback about trial procedures, acceptability, health 
service use, costs to the patient and suggestions for improving the study and information on symptomatic house-
hold contacts were collected at the end of the study. Participants had the option to fill the daily and end-of-study 
forms online or on paper and return them to the laboratory.
Study Procedures. Intervention arm were taught to prepare the hypertonic saline, perform HSNIG and doc-
umented the number of times/day and side-effects. They could either prepare 100 ml of hypertonic saline for 
a single use or prepare in bulk in a clean flask for use during the day. Instructions on how to make the solution 
and perform HSNIG are in Supplementary Methods and in www.elvisstudy.com. Control arm managed URTI 
as they normally did. As the hypothesis was chloride ion mediated antiviral effect, normal saline could not be 
used as a placebo. As sodium bicarbonate was uncomfortable in the authors personal experience, we opted for 
not including a placebo arm. The rationale for not including a saline placebo arm is elaborated in the discussion. 
Participants documented OTCM use and were asked to contact to their GP if unwell. The trial nurse helped 
participants in the intervention arm identify the highest concentration of HS they were comfortable with (from 
3%, 2.5%, 2.0% and 1.5%). Intervention arm were taught how to prepare HS and perform HSNIG with vid-
eos (www.elvisstudy.com) and given the opportunity to perform HSNIG under supervision. Cornish sea salt, 
digital-measuring spoon, bowls and flask were provided with instructions to perform HSNIG as many times as 
required (expected frequency up to 6 times/day for the first two days, reducing in frequency from day 3 as symp-
toms improved).
Mid-turbinate swab collection. The trial nurse collected a mid-turbinate swab (day 0) and taught partic-
ipants on how to collect samples first thing in the morning on days 1–4 (before HSNIG was performed that day 
in the intervention arm). Flocked mid-turbinate swabs and eNAT transport medium (Copan, Italy) and Royal 
Mail Safebox were provided with instructions to package and return the samples to the Department of Laboratory 
Medicine, RIE for testing. Instructions on how to collect and return mid-turbinate swabs are in Supplementary 
Methods.
Virological testing and quantification. Mid-turbinate swabs were tested by an in-house polymerase chain reac-
tion (PCR). The panel included, influenza virus A&B, respiratory syncytial virus (RSV), parainfluenza viruses 
(PIV) 1–3, human metapneumovirus (HMPV), adenovirus, rhinovirus, enterovirus, parechovirus, bocavirus, 
coronaviruses (COV) OC43, NL63, 229E, HKU1, and mycoplasma. Day 0 samples were initially tested. Where an 
agent was identified, all samples (day 0 – day 4) were tested in parallel and the cycle threshold value (CT value) 
converted to log10 to estimate change in viral shedding. CT was capped at 40 as samples with CT values above this 
level was unlikely to be positive on repeat testing. CT values were converted to log10 using this formula (40-CT of 
sample)/3.3 (a CT of 3.3 represents a log change in viral load by PCR). Since the baseline sample was tested on two 
separate occasions, reproducibility of testing was assessed by comparing the two results. Inter-assay variation was 
expected to be <0.5 log10. Where consecutive samples had undetectable virus, the first sample that was undetect-
able was treated as the end-point for viral shedding analysis. For the intervention arm, since NaCl could have an 
antiviral effect, the day with the lowest shedding when HSNIG was being performed was treated as the end-point. 
Where HSNIG was stopped earlier than 4 days, since swabs were collected first thing in the morning, the day 
after HSNIG was stopped was considered the end-point. Hence for the intervention arm, the end-point was day 4 
[apart from participant numbers 1, 5, 7, 13, 16, 17, 18 and 19 where it was day 3; 2 (rhinovirus), 14, and 15 where 
it was day 2; and 11 and 12 where it was day 1]. Two individuals had dual viral infections in their specimen. Both 
viruses were included for viral shedding analysis.
To determine if there was reduction in viral shedding, the log10 value of the day 0 sample was subtracted from 
the log10 value of the end-point. Negative values indicate a reduction in viral shedding and positive values indicate 
an increase in viral shedding. To determine the reduction in viral shedding per day, these values were divided by 
the number of days of follow-up. The proportion of individuals with reduction in viral shedding by ≥0.5 log10/
day was then calculated.
statistical analysis. We used SAS v9.4 software for statistical analysis. For categorical data, we present num-
bers and percentages. For continuous data, we present mean (standard deviation) or median (interquartile range 
(IQR)) as appropriate. Binomial test for the comparisons of proportions was used to examine differences in pro-
portions and presented along with 95% CI for differences in proportions or chi-square tests depending on the 
number of groups. To compare differences between treatment arms, two-sample t-tests or Mann-Whitney tests 
were used, as appropriate.
Participants were considered in the groups to which they were randomised irrespective of treatment received 
for analysis. Due to the way the data were collected, baseline information was available for all participants. Any 
subsequent information was the result of participants returning the diary card, potential non-return of diary 
cards was accounted for by increasing our sample size to allow for drop-outs. In the cases where diary cards were 
not returned, we do not have any information beyond baseline and therefore we have not used any methods to 
impute any missing data.
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